1. Efficacy of Acupuncture and Moxibustion as a Subsequent Treatment after Second-Line Chemotherapy in Advanced Gastric Cancer
- Author
-
Zi-Yuan Zhu, Huai-Dong Liu, Qi Min, Ying Huang, Fu-Jin Jiang, Yongjie Zhang, and Hai-Qing Hua
- Subjects
Oncology ,0303 health sciences ,medicine.medical_specialty ,Chemotherapy ,Article Subject ,business.industry ,medicine.medical_treatment ,GATA3 ,Moxibustion ,Advanced gastric cancer ,Second line chemotherapy ,Peripheral blood mononuclear cell ,Other systems of medicine ,03 medical and health sciences ,0302 clinical medicine ,Real-time polymerase chain reaction ,Complementary and alternative medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Acupuncture ,business ,RZ201-999 ,Research Article ,030304 developmental biology - Abstract
Objective. To explore whether acupuncture and moxibustion can prevent disease progression of advanced gastric cancer patients completing second-line chemotherapy and, if so, the related mechanism. Method. Progression-free survival (PFS) and overall survival (OS) were main outcome measures. The real-time quantitative PCR was used to detect the expression of genes including T-bet, IFN-γ, GATA3, and IL-4 in peripheral blood mononuclear cells (PBMCs). IL-4, IL-6, Ca199, CRP, and IFN-γ in plasma levels were checked. Results. 170 patients were randomly assigned in a 3 : 2 ratio to receive either acupuncture and moxibustion or sham acupuncture until progression. 135 patients were included in the primary analysis. Both PFS and OS in treatment group were proven to be better than control group. Acupuncture and moxibustion promoted typical Th1 cells drifting, as confirmed by increased T-bet/IFN-γ and decreased GATA3/IL-4 in mRNA levels from PBMCs, as well as upregulating IFN-γ and downregulating IL-4 in plasma levels. IL-6, Ca199, and CRP in plasma levels were also reduced by acupuncture and moxibustion. Conclusions. Acupuncture and moxibustion can prolong PFS and OS of advanced gastric cancer patients completing second-line chemotherapy by reversing Th1/Th2 shift and attenuating inflammatory responses.
- Published
- 2020